DK3292105T3 - Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) - Google Patents

Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) Download PDF

Info

Publication number: DK3292105T3
Authority: DK; Denmark
Prior art keywords: pyrazold; flap; inhibitors; activating protein; derivatives used
Prior art date: 2015-05-04

Application number

DK16720116T

Other languages

English (en)

Inventor

Johan Olof Broddefalk

Hans Fredrik Emtenäs

Kenneth Lars Granberg

Malin Anita Lemurell

Daniel Tor Pettersen

Alleyn Thomas Plowright

Lars Johan Andreas Ulander

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-04

Filing date

2016-05-03

Publication date

2019-12-09

2016-05-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2019-12-09 Application granted granted Critical

2019-12-09 Publication of DK3292105T3 publication Critical patent/DK3292105T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK16720116T 2015-05-04 2016-05-03 Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) DK3292105T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562156424P	2015-05-04	2015-05-04
PCT/EP2016/059848 WO2016177703A1 (en)	2015-05-04	2016-05-03	Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors

Publications (1)

Publication Number	Publication Date
DK3292105T3 true DK3292105T3 (da)	2019-12-09

Family

ID=55910253

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19199606.5T DK3670499T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK16720116T DK3292105T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19199606.5T DK3670499T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)

Country Status (38)

Country	Link
US (5)	US10183947B2 (da)
EP (2)	EP3292105B1 (da)
JP (1)	JP6564062B2 (da)
KR (1)	KR102623474B1 (da)
CN (1)	CN107646036B (da)
AR (1)	AR104512A1 (da)
AU (1)	AU2016258874B2 (da)
BR (1)	BR112017022757B1 (da)
CA (1)	CA2983668C (da)
CL (1)	CL2017002660A1 (da)
CO (1)	CO2017011506A2 (da)
CR (1)	CR20170513A (da)
CY (2)	CY1122689T1 (da)
DK (2)	DK3670499T3 (da)
DO (1)	DOP2017000244A (da)
EA (1)	EA032221B1 (da)
ES (2)	ES2760466T3 (da)
GT (1)	GT201700220A (da)
HK (1)	HK1245255A1 (da)
HR (2)	HRP20211993T1 (da)
HU (2)	HUE056875T2 (da)
IL (1)	IL255069B (da)
LT (1)	LT3670499T (da)
ME (1)	ME03663B (da)
MX (1)	MX2017013571A (da)
MY (1)	MY186647A (da)
PE (1)	PE20180247A1 (da)
PH (1)	PH12017502112A1 (da)
PL (2)	PL3292105T3 (da)
PT (2)	PT3670499T (da)
RS (2)	RS62729B1 (da)
SG (1)	SG11201708558RA (da)
SI (2)	SI3292105T1 (da)
SV (1)	SV2017005549A (da)
TN (1)	TN2017000458A1 (da)
TW (1)	TWI718146B (da)
WO (1)	WO2016177703A1 (da)
ZA (1)	ZA201708189B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR104512A1 (es)	2015-05-04	2017-07-26	Astrazeneca Ab	Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
EA201990957A1 (ru) *	2016-10-28	2019-09-30	Астразенека Аб	Кристаллическая форма (1r,2r)-2-[4-(3-метил-1h-пиразол-5-ил)бензоил]-n-(4-оксо-4,5,6,7-тетрагидропиразоло[1,5-a]пиразин-3-ил)циклогексанкарбоксамида
CN110169969B (zh) *	2019-06-28	2022-05-27	南京医科大学	Mk571在制备预防和治疗心脏病药物中应用
CN111084775A (zh) *	2020-02-17	2020-05-01	牡丹江医学院	一种用于治疗癫痫的药物组合物
CN111419800B (zh) *	2020-04-23	2021-03-19	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	用于***的药物制剂及其制备方法
CN111643498B (zh) *	2020-07-20	2021-05-07	黑龙江中医药大学	一种治疗肾结石的药物组合物及其用途
CN111714499B (zh) *	2020-07-27	2021-05-11	黑龙江中医药大学	一种用于治疗***的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL109254A (en)	1993-04-29	1999-03-12	Zeneca Ltd	History of the tetrahydropyran and tetrahydropuran site preparation and pharmaceutical preparations containing them
US5773422A (en)	1996-01-29	1998-06-30	Komer; Gene	Avermectin formulation
AU2004270394A1 (en) *	2003-09-10	2005-03-17	Gpc Biotech Ag	Heterobicyclic compounds as pharmaceutically active agents
GB2431927B (en) *	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200815351A (en) *	2006-05-02	2008-04-01	Astrazeneca Ab	Novel compounds
JP2010518025A (ja) *	2007-02-05	2010-05-27	アミラファーマシューティカルス，インコーポレーテッド	５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
GB0702456D0 (en) *	2007-02-08	2007-03-21	Astrazeneca Ab	New combination
MX2009011357A (es) *	2007-04-20	2009-11-05	Schering Corp	Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
MX2009011923A (es) *	2007-05-10	2009-11-18	Amr Technology Inc	Tetrahidrobenzo-1,4-diazepinas aril- y heteroaril-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.
EP2207547A4 (en) *	2007-10-05	2010-11-17	Amira Pharmaceuticals Inc	PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE
AR104512A1 (es) *	2015-05-04	2017-07-26	Astrazeneca Ab	Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)

2016
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active IP Right Grant
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 MX MX2017013571A patent/MX2017013571A/es active IP Right Grant
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en active Application Filing
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112A1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
2018
- 2018-04-06 HK HK18104539.0A patent/HK1245255A1/zh unknown
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-02 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
2023
- 2023-02-27 US US18/174,832 patent/US20230219967A1/en active Pending

Also Published As

Publication number	Publication date
US10508119B2 (en)	2019-12-17
NZ737672A (en)	2020-11-27
CR20170513A (es)	2018-02-13
EP3670499A1 (en)	2020-06-24
PL3670499T3 (pl)	2022-02-14
US20190084991A1 (en)	2019-03-21
MY186647A (en)	2021-08-03
SG11201708558RA (en)	2017-11-29
DOP2017000244A (es)	2017-11-15
HK1245255A1 (zh)	2018-08-24
GT201700220A (es)	2018-12-19
PL3292105T3 (pl)	2020-04-30
CN107646036B (zh)	2020-05-19
BR112017022757A2 (pt)	2018-07-17
US20180237439A1 (en)	2018-08-23
SV2017005549A (es)	2018-03-12
ZA201708189B (en)	2018-11-28
PE20180247A1 (es)	2018-02-02
SI3670499T1 (sl)	2022-02-28
US11691978B2 (en)	2023-07-04
DK3670499T3 (da)	2022-01-03
RS62729B1 (sr)	2022-01-31
AU2016258874B2 (en)	2020-04-30
HUE056875T2 (hu)	2022-03-28
ES2760466T3 (es)	2020-05-14
US20210355127A1 (en)	2021-11-18
TWI718146B (zh)	2021-02-11
LT3670499T (lt)	2021-12-27
JP2018514535A (ja)	2018-06-07
TN2017000458A1 (en)	2019-04-12
US20230219967A1 (en)	2023-07-13
PT3670499T (pt)	2021-12-24
CO2017011506A2 (es)	2018-01-31
WO2016177703A1 (en)	2016-11-10
HRP20192172T1 (hr)	2020-02-21
HRP20211993T1 (hr)	2022-04-01
EA201792341A1 (ru)	2018-05-31
RS59671B1 (sr)	2020-01-31
US20200157113A1 (en)	2020-05-21
CY1122689T1 (el)	2021-03-12
CY1125179T1 (el)	2023-03-24
CA2983668A1 (en)	2016-11-10
ES2902139T3 (es)	2022-03-25
SI3292105T1 (sl)	2020-01-31
EP3292105B1 (en)	2019-10-02
EP3670499B1 (en)	2021-09-29
KR20180002784A (ko)	2018-01-08
PH12017502112B1 (en)	2018-05-07
IL255069A0 (en)	2017-12-31
PH12017502112A1 (en)	2018-05-07
MX2017013571A (es)	2018-02-26
AU2016258874A1 (en)	2017-12-14
US10183947B2 (en)	2019-01-22
KR102623474B1 (ko)	2024-01-09
CL2017002660A1 (es)	2018-04-13
PT3292105T (pt)	2019-12-13
AR104512A1 (es)	2017-07-26
CN107646036A (zh)	2018-01-30
HUE047445T2 (hu)	2020-04-28
TW201713625A (zh)	2017-04-16
ME03663B (me)	2020-07-20
US11001589B2 (en)	2021-05-11
IL255069B (en)	2019-12-31
EP3292105A1 (en)	2018-03-14
CA2983668C (en)	2023-06-27
BR112017022757B1 (pt)	2023-02-23
EA032221B1 (ru)	2019-04-30
JP6564062B2 (ja)	2019-08-21

Publication	Publication Date	Title
DK3472167T3 (da)	2022-09-05	Heterocykliske forbindelser som immunomodulatorer
DK3442980T3 (da)	2021-08-30	Heterocykliske forbindelser som ret-kinase-hæmmere
DK3464271T3 (da)	2020-06-15	Pyrazolderivater som plasma-kallikreininhibitorer
DK3377488T3 (da)	2022-10-03	Heterocykliske forbindelser som immunomodulatorer
DK3302448T3 (da)	2024-02-05	Erstattede heterocyclylafledninger som cdk-inhibitore
DK3371190T3 (da)	2022-05-23	Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3394033T3 (da)	2021-01-04	Heterocykliske forbindelser som immunmodulatorer
DK3461821T3 (da)	2020-08-17	Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3119762T3 (da)	2021-08-30	Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK3294738T3 (da)	2021-06-28	Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
DK3556752T3 (da)	2022-03-07	N-((het)arylmethyl)-heteroaryl-carboxamidforbindelser som plasmakallikreininhibitorer
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
DK3356345T3 (da)	2024-02-12	Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
DK3164130T3 (da)	2019-10-28	Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym
DK3313832T3 (da)	2021-04-19	3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3094631T3 (da)	2019-05-06	Pyrimidinyloxybenzenderivater som herbicider
DK3271349T3 (da)	2019-08-05	Benzimidazolederivater som bromodomain-inhibitorer
DK3436435T3 (da)	2021-08-09	Substituerede indolderivater som inhibitorer af replikation af denguevirus
DK3350163T3 (da)	2020-03-16	Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
DK3292105T3 (da)	2019-12-09	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK3244886T3 (da)	2022-01-17	Indolderivater som inhibitorer af dengue virus-replikation
DK3601225T3 (da)	2021-08-16	Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3768674T3 (da)	2024-02-19	Aminopyrimidinderivater som ctps1-hæmmere
DK3580220T3 (da)	2022-01-10	Aminotriazolpyridiner som kinasehæmmere
DK3348556T3 (da)	2020-08-03	Heteroarylamider som hæmmere af proteinaggregering